Your session is about to expire
← Back to Search
Vudalimab + Chemotherapy/Targeted Therapy for Prostate Cancer
Study Summary
This trial will study the safety and effectiveness of XmAb20717 as a treatment for patients with metastatic prostate cancer who have been previously treated with other cancer therapies.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not received a live-virus vaccine in the last 30 days.I have recovered from previous cancer treatment side effects to a mild level.I do not have HIV or hepatitis B/C, or it is under control.I am on hormone therapy to lower testosterone and willing to continue it.I am willing and able to follow the study's schedule.I have experienced severe side effects from previous immunotherapy.My prostate cancer diagnosis was confirmed through a tissue examination.I am fully active or restricted in physically strenuous activity but can do light work.I am currently on cancer treatment excluding hormone therapy.I have previously been treated with docetaxel.I haven't had cancer treatment in the last 2 weeks.My condition worsened despite previous treatments.I have previously been treated with specific immunotherapy.My prostate cancer is worsening despite treatment.My blood, liver, kidney, heart functions are normal and I don't have autoimmune diseases.I can provide samples of my cancer that has spread, or I agree to a biopsy.I have had a serious infection recently.I am 18 years old or older.My cancer has been genetically tested and falls into one of the specific groups.
- Group 1: Cohort D - MSI-H, MMRD or TMB-H
- Group 2: Cohort E - No Targetable Mutations
- Group 3: Cohort B - HRD/CDK12 PARP - Progressors
- Group 4: Cohort A - AVPCa
- Group 5: Cohort C - HRD/CDK12 PARP Naïve
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the administration sanctioned XmAb20717 + carboplatin + cabazitaxel?
"This drug combination, XmAb20717 + carboplatin + cabazitaxel, received a score of 2 due to the presence of Phase 2 trial data that provides some assurance as far as safety is concerned but no evidence concerning efficacy."
What is the current population of participants in this trial?
"The sponsor of this investigation, Xencor Inc., requires 85 participants that meet the inclusion criteria to carry out their research. These trials will take place in Duarte, California at City of Hope and Comprehensive Cancer Centers of Nevada located in Las Vegas, Nevada."
What medical condition is XmAb20717 + carboplatin + cabazitaxel commonly meant to treat?
"XmAb20717 + carboplatin + cabazitaxel is regularly employed to treat those who have been exposed to chemotherapy. It may also be effective in treating advanced thymoma, testicular cancer, carcinomas, and neuroendocrine tumours."
What findings have been reported from investigations using XmAb20717 in conjunction with carboplatin and cabazitaxel?
"XmAb20717 + carboplatin + cabazitaxel was initially researched in 2002 at Bristol Royal Hospital for Children. Since then, 939 studies have been completed and 878 are currently active, the majority of which are conducted near Duarte, California."
What is the current number of clinical sites conducting this trial?
"At present, 11 sites across the country are researching this trial. From Duarte to Las Vegas and Iowa City, patients can find a nearby center that is taking part in the study. Choosing a site close by reduces travel requirements for those who take part."
Are there any open positions available to participate in this research?
"According to the official documentation on clinicaltrials.gov, this medical trial is still actively enrolling patients as of May 24th 2022 after being posted in October 2021."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger